5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 6.56▼ | 6.37▲ | 6.37▲ | 6.38▲ | 6.21▲ |
MA10 | 6.53▼ | 6.22▲ | 6.22▲ | 6.17▲ | 6.88▼ |
MA20 | 6.15▲ | 5.84▲ | 5.86▲ | 6.08▲ | 7.98▼ |
MA50 | 5.74▲ | 6.50▲ | 6.95▼ | 6.97▼ | 12.59▼ |
MA100 | 7.08▼ | 7.08▼ | 7.03▼ | 7.99▼ | 118.46▼ |
MA200 | 7.28▼ | 8.17▼ | 8.22▼ | 11.11▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.029▲ | 0.149▲ | 0.160▲ | 0.130▲ | 0.938▲ |
RSI | 54.902▲ | 53.993▲ | 52.903▲ | 50.748▲ | 33.385▼ |
STOCH | 66.739 | 67.095 | 68.197 | 69.093 | 21.499 |
WILL %R | -37.118 | -23.810▲ | -23.810▲ | -31.636 | -72.714 |
CCI | 24.467 | 86.127 | 85.948 | 123.803▲ | -37.808 |
Sunday, April 27, 2025 05:00 PM
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination ...
|
Thursday, April 24, 2025 05:00 PM
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination ...
|
Thursday, April 17, 2025 05:00 PM
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
30/04/25 | 6.50 | 7.09 | 5.96 | 6.59 | 7,244 |
29/04/25 | 6.135 | 6.135 | 6.135 | 6.135 | 832 |
28/04/25 | 7.46 | 7.46 | 6.40 | 6.40 | 19,191 |
25/04/25 | 5.66 | 6.86 | 5.66 | 6.56 | 12,951 |
24/04/25 | 5.95 | 6.52 | 5.95 | 6.215 | 8,893 |
23/04/25 | 5.88 | 6.19 | 5.88 | 6.19 | 2,156 |
22/04/25 | 5.84 | 6.0934 | 5.41 | 5.88 | 12,281 |
21/04/25 | 6.19 | 6.19 | 5.6819 | 5.91 | 1,433 |
17/04/25 | 5.80 | 6.00 | 5.60 | 5.95 | 5,262 |
16/04/25 | 4.91 | 5.89 | 4.91 | 5.89 | 176,415 |
|
|
||||
|
|
||||
|
|